CONSORT Statement 2006 - Checklist for Non-inferiority and Equivalence Trials

Items to include when reporting a non-inferiority or equivalence randomized trial

Please note: This is an open-label phase 2/3 study that evaluates safety and non-inferiority of study vaccination in 2 cohorts of participants. The checklist has been correspondingly completed to indicate compliance with guidelines where applicable. NA=not applicable.

PAPER SECTION And topic	Item	Descriptor	Reported on Page #
TITLE & ABSTRACT	1	How participants were allocated to interventions (e.g., "random allocation", "randomized", or "randomly assigned"), specifying that the trial is a non-inferiority or equivalence trial.	NA: not a randomized trial; participants were
			vaccine as described (pg. 5, & Fig. 1, pg.19)
INTRODUCTION Background	2	Scientific background and explanation of rationale, including the rationale for using a non-inferiority or equivalence design.	4; Supplement pg.4-6
METHODS Participants	3	Eligibility criteria for participants (detailing whether participants in the non-inferiority or equivalence trial are similar to those in any trial(s) that established efficacy of the reference treatment) and the settings and locations where the data were collected.	5; Supplement, pg. 4-6
Interventions	4	Precise details of the interventions intended for each group detailing whether the reference treatment in the non-inferiority or equivalence trial is identical (or very similar) to that in any trial(s) that established efficacy, and how and when they were actually administered.	5; Supplement pg. 4
Objectives	5	<u>Specific objectives and hypotheses</u> , including the hypothesis concerning non-inferiority or equivalence.	7-9; Supplement, pg. 6-9 and 16-17
Outcomes	6	Clearly defined primary and secondary outcome measures detailing whether the outcomes in the non-inferiority or equivalence trial are identical (or very similar) to those in any trial(s) that established efficacy of the reference treatment and, when applicable, any methods used to enhance the quality of measurements (e.g., multiple observations, training of assessors).	7-9; Supplement, pg. 6-9
Sample size	7	How sample size was determined detailing whether it was calculated using a non-inferiority or equivalence criterion and specifying the margin of equivalence with the rationale for its choice. When applicable, explanation of any interim analyses and stopping rules (and whether related to a non-inferiority or equivalence hypothesis).	Supplement, pg. 7
Randomization Sequence generation	8	Method used to generate the random allocation sequence, including details of any restrictions (e.g., blocking, stratification)	NA: not randomized
Randomization Allocation concealment	9	Method used to implement the random allocation sequence (e.g., numbered containers or central telephone), clarifying whether the sequence was concealed until interventions were assigned.	NA: not randomized
Randomization Implementation	10	Who generated the allocation sequence, who enrolled participants, and who assigned participants to their groups.	NA: not randomized
Blinding (masking)	11	Whether or not participants, those administering the interventions, and those assessing the outcomes were blinded to group assignment. If done, how the success of blinding was evaluated.	NA: open-label trial
Statistical methods	12	Statistical methods used to compare groups for primary outcome(s), specifying whether a one or two-sided confidence interval approach was used. Methods for additional analyses, such as subgroup analyses and adjusted analyses.	7-9; Supplement, pg. 6-8

		•	
RESULTS	13	Flow of participants through each stage (a diagram is	16; Figure 1
Participant flow		strongly recommended). Specifically, for each group report	
. artioipant now		the numbers of participants randomly assigned, receiving	
		intended treatment, completing the study protocol, and	
		analyzed for the primary outcome. Describe protocol	
		deviations from study as planned, together with reasons.	
Recruitment	14	Dates defining the periods of recruitment and follow-up.	9-10
Baseline data	15	Baseline demographic and clinical characteristics of each	9 and Table 1, pg.
		group.	20
Numbers analyzed	16	Number of participants (denominator) in each group included	Table 2 pg. 21;
		in each analysis and whether the analysis was "intention-to-	Supplement, pg.
		treat" and/or alternative analyses were conducted. State the	12-15 and 22-28
		results in absolute numbers when feasible (e.g., 10/20, not	
		50%).	
Outcomes and	17	For each primary and secondary outcome, a summary of	11-12, Table 2;
estimation		results for each group, and the estimated effect size and its	21; Supplement,
		precision (e.g., 95% confidence interval). For the outcome(s)	p. 12-15 and 19-
		for which non-inferiority or equivalence is hypothesized, a figure	28
		showing confidence intervals and margins of equivalence may be	
		useful.	
Ancillary analyses	18	Address multiplicity by reporting any other analyses	7-9; Supplement,
		performed, including subgroup analyses and adjusted	pg. 6-8
		analyses, indicating those pre-specified and those	
		exploratory.	
Adverse events	19	All important adverse events or side effects in each	10 and Figure 2
		intervention group.	pg.17
DISCUSSION	20	Interpretation of the results, taking into account the non-	9-12
Interpretation		inferiority or equivalence hypothesis and any other study	
		hypotheses, sources of potential bias or imprecision and the	
		dangers associated with multiplicity of analyses and	
		outcomes.	
Generalizability	21	Generalizability (external validity) of the trial findings.	14-15
Overall evidence	22	General interpretation of the results in the context of current	13-14
		evidence.	

www.consort-statement.org